The Latest Breaking News from ABBV

AbbVie is scheduled to report its first-quarter results this month, with analysts anticipating a modest growth in earnings.

These three high-yield Dividend Kings have strong buy ratings and impressive growth potential, and analysts see big upside in these names.

Markets got a double dose of bad news about inflation and consumer confidence; next week, the Trump tariffs and Jobs report are likely to keep volatility high

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

AbbVie has outperformed the healthcare sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare spending and innovative technologies transforming patient care, companies like AbbVie (ABBV), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY) are tackling some of the biggest challenges and could be poised for long-term growth. Read more….

Dividend-growth stocks offer steady income and long-term value. With the Fed holding rates and inflation expected to ease, now is an opportune time to invest in companies like AbbVie (ABBV), Energy Transfer (ET), and Cheniere Energy (CQP) that consistently raise payouts. Read more….

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.

It’s easy to get caught up in market noise, but investing in companies backed by strong fundamentals and long-term growth potential can help investors stay the course even during market volatility. Thus, one could consider adding these three high-conviction pharmaceutical stocks, AbbVie (ABBV), Merck & Co. (MRK), and Bristol-Myers Squibb…

AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.